Latest News
- Further MP0250 clinical data and partner interest underline Molecular Partners’ continued progress of its proprietary oncology compounds
April 26, 2018 - Molecular Partners presented preliminary results from the ongoing phase 2 study of MP0250 at the European Myeloma Network Meeting in Turin
April 21, 2018
Latest Presentations
MP Corporate Presentation
March 13, 2018
MP presentation at the Cowen and Company 38th Annual Health Care Conference
March 13, 2018
Products
Molecular Partners is advancing a growing pipeline of DARPin therapies for the treatment of severe or life-threatening diseases, with an initial focus on oncology and ophthalmology. Its most advanced oncology candidate, MP0250, is for the treatment of solid tumors and hematological malignancies. In ophthalmology, the most advanced candidate is abicipar in wet age-related macular degeneration (wet AMD). It has been licensed to Allergan and is being tested in two phase III trials.
We tailor each DARPin® therapy to target single or multiple disease pathways responsible for serious and complex diseases, all in a single medicine.
